33 results
6-K
EX-99.1
BPTSY
Biophytis S.A.
11 Jul 24
Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
10:22am
will include analysis of mobility (via the 6-minute walk test) and body composition (assessment of fat and lean mass). A world-renowned medical expert
6-K
EX-99.1
BPTSY
Biophytis S.A.
20 Jun 24
Current report (foreign)
11:34am
development programmes for its drug candidate. With 40 years of history, Blanver has become an expert in infectious diseases, osteoporosis and metabolic
6-K
EX-99.1
BPTSY
Biophytis S.A.
11 Jun 24
Biophytis announces filing of an IND application
10:45am
at the Medical University of South Carolina. He is a worldwide recognized medical expert in the field of obesity and is currently President-Elect
6-K
EX-99.1
BPTSY
Biophytis S.A.
18 Apr 24
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
10:08am
Villareal is a world-wide expert in the field of obesity, especially in the management of patients with obesity. He was a key investigator in our SARA … -INT Phase 2 study in sarcopenia. Professor Francisco Guarner is a world-wide expert in the field of Internal Medicine, Gastroenterology and Hepatology
6-K
EX-99.1
we38lnmwwo7nuak
28 Nov 23
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board
10:47am
6-K
EX-99.1
la6v8bziz
11 Sep 23
Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia
9:52am
6-K
EX-99.1
1mxfgqi4fv
25 Aug 23
Biophytis receives a positive opinion for its SARA-31
12:29pm
F-1
m6510o
4 Aug 23
Registration statement (foreign)
4:18pm
6-K
EX-10.3
ff1y jrqy
21 Jul 23
Biophytis Announces $3.8 Million
6:01am
6-K
EX-10.4
pl74u
21 Jul 23
Biophytis Announces $3.8 Million
6:01am
20-F/A
ljkdtifbuihkm
28 Oct 21
Annual report (foreign) (amended)
5:16pm